Cochrane Clinical Answers
Cochrane Clinical Answers (CCAs) provide a readable, digestible, clinically focused entry point to rigorous research from Cochrane systematic reviews. They are designed to be actionable and to inform decision making at the point of care and have been added to relevant sections of the main Best Practice text.
- In preterm or low birth weight infants, do cyclo‐oxygenase inhibitors (COX‐I) help prevent morbidity and mortality?
- What are the effects of prostaglandin inhibitor drugs for the treatment of symptomatic patent ductus arteriosus (PDA)?
- How does ibuprofen compare with standard indomethacin therapy for preterm/low birth weight infants with patent ductus arteriosus (PDA)?
- In preterm infants with symptomatic patent ductus arteriosus, what are the benefits and harms of surgical compared with medical treatment with indomethacin?
- How does paracetamol (acetaminophen) compare with other interventions for treating preterm or low‐birthweight infants with patent ductus arteriosus (PDA)?
Use of this content is subject to our disclaimer